Clinician’s Guide to Prevention and Treatment of Osteoporosis
Open accessThe DOI matches its Crossref record; 101 of the 102 references it cites were found in a registry or an index; 41 of the 169 sources its claims cite were checked for support.
Abstract
The Clinician's Guide to Prevention and Treatment of Osteoporosis was developed by an expert committee of the National Osteoporosis Foundation (NOF) in collaboration with a multispecialty council of medical experts in the field of bone health convened by NOF. Readers are urged to consult current prescribing information on any drug, device, or procedure discussed in this publication.
Overview
CoChat Summary
TL;DR
This NOF Clinician’s Guide provides recommendations for prevention, risk assessment, diagnosis, and treatment of osteoporosis in postmenopausal women and men age 50 and older, including BMD testing, vertebral imaging, FRAX-based intervention thresholds, and FDA-approved pharmacotherapy. It emphasizes that osteoporosis is common, underdiagnosed, and treatable, with treatment thresholds and drug-specific fracture risk reductions summarized.
Key findings
- Osteoporosis affects more than 9.9 million Americans, with an additional 43.1 million having low bone density; about 1 in 2 Caucasian women and approximately 1 in 5 men will experience an osteoporosis-related fracture. Annually, 2 million fractures are attributed to osteoporosis, causing more than 432,000 hospital admissions, almost 2.5 million medical office visits, and about 180,000 nursing home admissions; costs are expected to rise to $25.3 billion by 2025. Only 23% of women age 67 or older who have an osteoporosis-related fracture receive either a BMD test or a prescription for osteoporosis drug in the 6 months after fracture.
- Pharmacologic treatment is recommended for hip or vertebral fracture, T-score ≤−2.5 at the femoral neck, total hip, or lumbar spine, or low bone mass (T-score between −1.0 and −2.5) with a 10-year hip fracture probability ≥3% or a 10-year major osteoporosis-related fracture probability ≥20% by US-adapted FRAX.
- Universal recommendations include calcium intake of 1000 mg/day for men 50–70 and 1200 mg/day for women 51 and older and men 71 and older; vitamin D 800–1000 IU/day for adults age 50 and older; regular weight-bearing and muscle-strengthening exercise; fall risk assessment and modification; smoking cessation; and avoidance of excessive alcohol.
- Selected drug efficacy data: alendronate reduces spine and hip fractures by about 50% over 3 years; zoledronic acid reduces vertebral fractures by 70%, hip fractures by 41%, and nonvertebral fractures by 25% over 3 years; denosumab reduces vertebral fractures by about 68%, hip fractures by about 40%, and nonvertebral fractures by about 20% over 3 years; teriparatide reduces vertebral fractures by about 65% and nonvertebral fragility fractures by about 53%; raloxifene reduces vertebral fractures by about 30% with prior vertebral fracture and about 55% without; calcitonin reduces vertebral fracture occurrence by about 30% but has not been shown to reduce nonvertebral fractures; ibandronate reduces vertebral fractures by about 50% but nonvertebral fracture reduction has not been documented.
Methods
- Design: guideline developed by an expert committee of the National Osteoporosis Foundation in collaboration with a multispecialty council of medical experts in bone health; recommendations apply to postmenopausal women and men age 50 and older.
- Data or sample: no primary study sample; the Guide synthesizes evidence including NHANES III prevalence estimates, the Women’s Health Initiative, FDA prescribing information, WHO FRAX, and cost-effectiveness analyses.
- Main analysis: expert consensus and evidence synthesis; absolute risk thresholds for pharmacologic intervention were guided by a cost-effectiveness analysis; diagnostic assessment uses central DXA, vertebral imaging, and US-adapted WHO FRAX.
Limitations
- Stated: FRAX underestimates fracture risk in patients with recent fractures, multiple osteoporosis-related fractures, and increased fall risk; it has not been validated for lumbar spine BMD, is not intended for younger adults or children, and has not been validated in patients currently or previously treated with osteoporosis pharmacotherapy.
- Stated: evidence of efficacy beyond 5 years is limited; rare safety concerns such as osteonecrosis of the jaw and atypical femur fractures become more common beyond 5 years; there are relatively few data confirming fracture risk reductions with pharmacotherapy in patients selected by low bone mass plus FRAX thresholds; fracture data are limited in glucocorticoid-induced osteoporosis and in men; and in the absence of head-to-head trials, direct comparisons of risk reduction among drugs should be avoided.
- Evident: the text does not report a systematic search strategy or formal evidence-grading system; the therapeutic thresholds are described as clinical guidance only and “not rules,” requiring individualized clinical judgment.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Micrographs of normal vs. osteoporotic bone [9], from Dempster et al., with permission of The American Society for Bone and Mineral Research [9]](https://figures.cochat.ai/paper-figures/d609b75c87444980afa9b5aebc701061/clinicians-guide-to-prevention-and-treatment-of-osteoporosis-figure-1.jpg)
![Fig. 2 Pathogenesis of osteoporosis-related fractures, from Cooper and Melton, with modification [10]](https://figures.cochat.ai/paper-figures/ff3ff2f3f4b84a5bbd00a8cc79080d62/clinicians-guide-to-prevention-and-treatment-of-osteoporosis-figure-2.jpg)

Verification
Claims the paper makes
29 Valid · 18 Not valid · 68 Not checked · 17 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Raloxifene is also indicated for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis [83–86].”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Pharmacologic therapy > Estrogen agonist/antagonist (formerly known as SERMs): Raloxifene
What the sources say
- Not checked — no full text of the sourcecites [83] Cauley JA Norton L Lippman ME Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation Breast Cancer Res Treat 2001 65 2 125 134 10.1023/A:1006478317173 11261828 source
- Disputedcites [84] Martino S Cauley JA Barrett-Connor E CORE Investigators Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene J Natl Cancer Inst 2004 96 23 1751 1761 10.1093/jnci/djh319 15572757 sourceExperimental — accuracy not yet measured
The introduction (p. 1) says raloxifene was approved for preventing and treating postmenopausal osteoporosis, while tamoxifen was the only agent approved in the United States to reduce breast cancer incidence. Although the CORE results (p. 5) show reduced invasive breast cancer incidence with raloxifene, they do not support the claim that breast cancer risk reduction was an approved indication. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Not checked — no full text of the sourcecites [85] Vogel VG Costantino JP Wickerham DL National Surgical Adjuvent Breast and Bowel Project (NSABP) Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial JAMA 2006 295 23 2727 2741 10.1001/jama.295.23.joc60074 16754727 source
- Partly supportedcites [86] Barrett-Connor E Mosca L Collins P Raloxifene Use for The Heart (RUTH) Trial Investigators Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women N Engl J Med 2006 355 2 125 137 10.1056/NEJMoa062462 16837676 sourceExperimental — accuracy not yet measured
The Primary Outcomes (p. 5) report that raloxifene reduced invasive breast cancer in the RUTH trial, and the introductory text (p. 2) reports a similar finding from MORE, an osteoporosis-treatment trial. The paper does not state that breast-cancer risk reduction is an approved indication for postmenopausal women with osteoporosis; RUTH enrolled women with or at increased risk for coronary heart disease. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Ibandronate reduces the incidence of vertebral fractures by about 50 % over 3 years, but reduction in risk of nonvertebral fracture with ibandronate has not been documented [50].”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Pharmacologic therapy > Bisphosphonates
What the sources say
- Disputedcites [50] Chesnut CH 3rd Skag A Christiansen C Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis J Bone Miner Res 2004 19 18 1241 1249 10.1359/JBMR.040325 15231010 sourceExperimental — accuracy not yet measured
The Clinical osteoporotic nonvertebral fractures section reports a statistically significant 69% reduction with daily ibandronate in women with a baseline femoral-neck BMD T score below −3.0. The Discussion cautions that this was a post hoc analysis and says there was no significant reduction in the overall population, but the unqualified claim that a reduction has not been documented overlooks the reported subgroup finding. Page numbers were not provided in the supplied passages. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A vertebral fracture is consistent with a diagnosis of osteoporosis, even in the absence of a bone density diagnosis, and is an indication for pharmacologic treatment with osteoporosis medication to reduce subsequent fracture risk [18, 21].”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Vertebral imaging
What the sources say
- Not checked — no full text of the sourcecites [18] Kanis JA Melton LJ 3rd Christiansen C Johnston CC Khaltaev N The diagnosis of osteoporosis J Bone Miner Res 1994 9 8 1137 1141 10.1002/jbmr.5650090802 7976495 source
- Supportedcites [21] Melton LJ Chrischilles EA Cooper C Lane AW Riggs BL How many women have osteoporosis? J Bone Miner Res 2005 20 5 886 892 10.1359/jbmr.2005.20.5.886 15931736 source
The conclusion (OSTEOPENIA, p. 6) distinguishes osteoporosis assessed by bone mineral measurements from established osteoporosis assessed by the occurrence of specific fractures. The introduction (p. 2) identifies vertebral fractures among the principal osteoporosis-related fractures, supporting the stated diagnosis without a bone-density diagnosis. (LLM, conf=0.91)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Help determine adequacy of patient compliance and persistence with osteoporosis therapy”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Biochemical markers of bone turnover
What the sources say
- Partly supportedcites [25] Burch J Rice S Yang H Neilson A Stirk L Francis R Holloway P Selby P Craig D Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups Health Technol Assess (Winchester, England) 2014 18 11 1 206 PMC4781229 24534414 sourceExperimental — accuracy not yet measured
The review’s “Compliance and persistence” section describes a model in which a bone turnover marker result could lead to a conclusion that compliance or treatment response was inadequate, but notes that the model did not include test-accuracy data. “Measures of adherence” says that a marker-identified non-response could reflect non-compliance or non-persistence, among several other causes. The source therefore supports markers as a possible clue, not as a way to determine the adequacy of both compliance and persistence. (LLM, conf=0.83)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Predict magnitude of BMD increases with FDA-approved therapies”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Biochemical markers of bone turnover
What the sources say
- Partly supportedcites [25] Burch J Rice S Yang H Neilson A Stirk L Francis R Holloway P Selby P Craig D Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups Health Technol Assess (Winchester, England) 2014 18 11 1 206 PMC4781229 24534414 sourceExperimental — accuracy not yet measured
The Clinical Effectiveness and Cost-Effectiveness Evidence section reports correlations between changes in bone turnover markers and BMD, including a statistically significant but weak correlation during teriparatide treatment. It also says not all correlations were significant and cautions that their usefulness varies by population. The review does not establish that markers predict the magnitude of BMD increases across FDA-approved therapies generally. (LLM, conf=0.84)
plainstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
87 more claims · 25 with their cited sources checked
Create a free account to see all 132 claims and to verify the 18 references still open.
- Probably not a substantial claim. 26
- It may state two separate claims as one. 25
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“this equated to a health care cost of $1088”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Previous studies31,46,47,48 in emergency department patients have identified primarily benefits, including reductions in health care costs, medical retirement, and depressive symptoms.”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
Experimental — accuracy not yet measuredIn the citing paper
“yielding an uptake of 89.9%”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
In the citing paper
“this issue was addressed by instead performing a thorough cost accounting from 2 specific exemplar interventions.30,31”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Diagnostic assessment
“Screening BMD and vertebral imaging recommendations for men are outlined in Table 8.”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Additional bone densitometry technologies
“Table: Table 8 Additional bone densitometry technologies”
Citations
Cites
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602
Incidence and Economic Burden of Osteoporosis-Related Fractures in the United States, 2005–2025
Burge, R., Dawson-Hughes, B., Solomon, D. H., Wong, J. B., King, A., & Tosteson, A. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.061113 · Cited by 4,026
Interventions for preventing falls in older people living in the community
Gillespie, L. D., Robertson, M. C., Gillespie, W. J., Sherrington, C., Gates, S., Clemson, L., & Lamb, S. E. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007146.pub3 · Cited by 3,966
Professor Kanis, J. A., Melton, L. J., Christiansen, C., Johnston, C. C., & Khaltaev, N. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650090802 · Cited by 3,849
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489 · cited 1×
“by about 40 %, and nonvertebral fractures by about 20 % over 3 years [56].”
BackgroundDecreased bioavailability of vitamin D in obesity
Wortsman, J., Matsuoka, L. Y., Chen, T. C., Lu, Z., & Holick, M. F. (2000) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/72.3.690 · Cited by 3,204 · cited 1×
“This regimen should be followed by maintenance therapy of 1500–2000 IU/day or whatever dose is needed to maintain the target blood level [37, 38].”
Background
Research works printed but not linked: 4
- Office of the Surgeon General (US) (2004) Bone health and osteoporosis: a report of the Surgeon General. Office of the Surgeon General (US), Rockville (MD). Available from: http://www.ncbi.nlm.nih.gov/books/NBK45513/. Accessed March 2014 20945569
- National Osteoporosis Foundation Physician’s guide to prevention and treatment of osteoporosis 2005 Washington, DC National Osteoporosis Foundation
- Institute of Medicine (US) Committee to review dietary reference intakes for vitamin D and calcium (2011). In: Ross AC, Taylor CL, Yaktine AL et al (eds) Dietary reference intakes for calcium and vitamin D. National Academies Press (US), Washington (DC). Available from: http://www.ncbi.nlm.nih.gov/books/NBK56070/. Accessed March 2014 21796828
- Cummings, SR, San Martin J, McClung MR et al (2009) FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361(8):756–765. (Erratum in: N Engl J Med. 2009;36(10):191) 19671655 · DOI · Paper page
Cited by
Items 3,701–3,800 of 4,108
Cao, C., Huang, X., Xiao, L., Deng, R., Wen, H., Li, X., Chen, Y., & Li, Y. (2022) · Research Square · doi:10.21203/rs.3.rs-2255039/v1
Reis, T. G. (2021) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.87.2021.tde-24112022-121110
Anand, V. K., Sharma, L. K., Kumar, V., et al. (2022) · Proceedings of the National Academy of Sciences India Section B Biological Sciences · doi:10.1007/s40011-022-01403-w
“Although, the long-term usage of these medications results in various clinical complications such as musculoskeletal pain, hypercalcemia, osteonecrosis of the jaw, endometrial, and breast cancer [5].”
BackgroundOsteoporosis postmenopáusica: relevancia de la búsqueda estructurada de causas secundarias
Jiménez, M., Henríquez, C., Miranda, F., et al. (2022) · Revista médica de Chile · doi:10.4067/s0034-98872022000500597
PENERAPAN STS DI DESA DAYA TARIK MUSIK KOTA AMBON MEMBERDAYAKAN GANDARIA ENDEMIK MALUKU
Papilaya, P. M., Sinay, H., & Karuwal, R. L. (2022) · PAKEM Jurnal Pengabdian Kepada Masyarakat · doi:10.30598/pakem.2.1.24-45
“Bila asupan tidak adekuat puncak masa tulang kurang, sehingga pada kehidupan kemudian hari dapat menyebabkan osteoporosis, sebaliknya jika kelebihan akan menyebabkan timbulnya batu ginjal, mungkin klasifikasi jaringan lunak dan konstipasi (Cosman et al., 2014).”
BackgroundBinti, R. S. C., Awalia, A., & Ferriastuti, W. (2022) · International Journal of Research Publications · doi:10.47119/ijrp1001161120234388
ELsheekh, M. E. (2023) · International Journal of Innovative Research in Medical Science · doi:10.23958/ijirms/vol08-i01/1597
Current trends and future perspectives of probiotics on human health: an overview
Mandal, S., & Mandal, N. C. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-90113-0.00005-5 · Cited by 2
FRAX® in Hemodialysis with Osteoporosis- A Registry Study
Huang, W., Wang, Y., Chen, C., et al. (2023) · Family Medicine and Primary Care Open Access · doi:10.29011/2688-7460.100210
Wiedza społeczeństwa na temat wpływu aktywności fizycznej na prewencję i leczenie osteoporozy
Barłowska-Trybulec, M., & Gosek, A. (2022) · Sztuka Leczenia · doi:10.4467/18982026szl.22.013.16672 · Cited by 2
Pietrzyk, B. Z. (2022) · Austin Journal of Orthopedics & Rheumatology · doi:10.26420/austinjorthopaderheumatol.2022.1112
del Azuay, U., Jerves-Andrade, M., Ruilova-González, L., del Azuay, U., Duque, G., & del Azuay, U. (2022) · doi:10.33324/ceuazuay.227
PREVALENCE OF OSTEOPOROTIC VERTEBRAL FRACTURES IN OLDER ADULTS FEMALES WITH TYPE 2 DIABETES MELLITUS
Mabrouk, E., Elhawary, G., Mousa, S., & Alsadany, M. A. (2022) · Ain Shams Medical Journal · doi:10.21608/asmj.2022.285470
Mensor, L. L., Rosim, M., Marchesan, T. H. M., Rigo, D., Sallum, F. S. V., & Amaral, L. (2022) · Jornal Brasileiro de Economia da Saúde · doi:10.21115/jbes.v14.n3.p259-266 · Cited by 1
Management of Risks Factors for Older Women: Osteoporosis and Cardiovascular Disease (CVD)
Quaas, P., Wade, K. S., & Quaas, A. M. (2023) · Springer eBooks · doi:10.1007/978-3-319-17002-2_47-2 · Cited by 2
Analysis of Factors Associated with Charcot Neuroarthropathy following Pancreatic Transplantation
Aida, N., Ito, T., Kurihara, K., et al. (2023) · Applied Sciences · doi:10.3390/app13042670
Study on the Impact of Diseases and Medical Treatments on Bone Mineral Density
Oumghar, I. A., Barkaoui, A., & Chabrand, P. R. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.110318
Garcia, D., Roy, S. G., & Hayeri, R. (2023) · doi:10.1002/9781119603627.ch23
Osteoporosis: prevention and management
Walker, J. A. (2023) · Nursing and Residential Care · doi:10.12968/nrec.2020.0015
Alterações do Funcionamento da Glândula da Tiróide
Silva, C. C. (2013) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · Cited by 3
OCAK, B. B., Peker, G. C., & Dağdeviren, M. (2022) · DergiPark (Istanbul University) · doi:10.32322/jhsm.1225479
Kasahara, K., Tanaka‐Mizuno, S., Tsuji, S., Ohashi, M., Kasahara, M., Kawasaki, T., & Murakami, T. (2023) · Research Square · doi:10.21203/rs.3.rs-2649675/v1
Indikatorët radiomorfometrikë - Vlefshmëria e tyre në detektimin e hershëm të osteoporozës
Shkodra-Brovina, M. (2022) · Revista e Stomatologëve të Kosovës · doi:10.59138/qpvfntnjwfkka
Boonyayothin, W. (2020) · Chula Digiverse · doi:10.58837/chula.the.2020.370
Lee, M. H., Yoon, S.-K., Kim, H., et al. (2023) · Drug Design Development and Therapy · doi:10.2147/dddt.s399264
Fractures after Initiation of a Drug Holiday in a Real- Life Setting
(2023) · doi:10.31038/edmj.2023712
“Medications for the treatment of osteoporosis [16]: Bisphosphonates: Alendronate, ibandronate, risedronate, and zoledronate.”
InfluentialLi, B., Zou, L., Chen, M., Liao, M., Gong, Z., Cheng, R., Ma, Z., Zheng, Q., & Wang, H. (2023) · Research Square · doi:10.21203/rs.3.rs-2822776/v1
Kadınlarda Fiziksel Aktivite ve Egzersizin Osteoporozu Önleme ve Tedavi Edici Rolü
Hareket, S., & Naz, İ. (2023) · Cumhuriyet Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi · doi:10.51754/cusbed.1181633
Boz, M., & Güzel, İ. (2021) · Indian Journal of Orthopaedics Surgery · doi:10.18231/j.ijos.2021.051
THE ASSOCIATION BETWEEN THE RISK OF FALLS AND CHARACTERISTICS OF GERIATRIC OSTEOPOROTIC PATIENTS
Trịnh, N. A., Trần, V. L., Nguyễn, X. T., et al. (2023) · VietNam Military Medical Unisversity · doi:10.56535/jmpm.v48i4.305
The Effect of Fish Scale Glue on the Osteogenic Performance of MC3T3-E1 Cells
王, 亚. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.134951
Exploring the Role of Urocortin in Osteoporosis
Ismail, O. M., El-Omar, O., & Said, U. N. (2023) · Cureus · doi:10.7759/cureus.38978 · Cited by 1
“When stopping HRT, bone volume may decrease quite substantially, so other agents must be used to maintain BMD [55].”
BackgroundInfluentialScreening of postmenopausal osteoporosis using Singh’s index
Chandra, D. M. D., & Sudhir, S. (2022) · International Journal of Clinical Obstetrics and Gynaecology · doi:10.33545/gynae.2022.v6.i6b.1237
Radanović, D., Matić, S., Pajic, S. S., Slijepčević, N., Knežević, S., Jakovljević, S., Elboursh, D., Mirčić, U., Čukić, B., & Savić, A. (2023) · Research Square · doi:10.21203/rs.3.rs-3047102/v1
Lednev, S. A., Юрова, И. Ю., Ledneva, V., et al. (2023) · Смоленский медицинский альманах · doi:10.37903/sma.2023.1.2
Pharmacological Treatment of Osteoporosis in Older Patients
Dejaeger, M., Dupont, J., Laurent, M. R., & Gielen, E. (2023) · Practical issues in geriatrics · doi:10.1007/978-3-031-28061-0_21
Association between walking speed and calcaneus stiffness index in older adults
Zhou, T., Wang, J., Li, Y., Lü, Y., Liu, J., Hong, J., Quan, M., Wang, D. W., & Chen, P. (2023) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-023-01447-6
“Dual-energy X-ray absorptiometry (DXA) is the gold standard for the diagnosis of osteoporosis and can objectively measure the bone mineral density (BMD) per unit area [6].”
BackgroundThe osteoporosis diagnosis and treatment gaps and risk factors among women aged ≥50 yearsPreprint
Shahrousvand, S., Ostovar, A., Fahimfar, N., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3024805/v1
Osteoporosis treatment with denosumab in routine clinical practice in Poland
Marcinowska-Suchowierska, E., Blicharski, T., Wielosz, E., et al. (2023) · Endokrynologia Polska · doi:10.5603/ep.a2023.0037
Improving the efficiency of methods for assessing bone tissue properties
Dinescu, O., Orban, E., Şipoş, R. S., et al. (2023) · Medic ro · doi:10.26416/med.153.3.2023.8189
Therkildsen, J., Rohde, P., Nissen, L., Thygesen, J., Hauge, E., Langdahl, B., Boettcher, M., Nyegaard, M., & Winther, S. (2023) · Osteoporosis International · doi:10.1007/s00198-023-06857-w
Güney, P. A., Irmak, İ., Halis, A. N., & Sarıbaş, E. (2023) · Turkish Journal of Internal Medicine · doi:10.46310/tjim.1206443
Bone Disease in Chronic Pancreatitis
Duggan, S. N. (2023) · doi:10.1002/9781119876007.ch55
Almalki, A., Almalki, M., Almahdi, H., et al. (2023) · Saudi Journal of Sports Medicine · doi:10.4103/sjsm.sjsm_2_23
Vertebral bone quality different in age and magnetic resonance imaging parametersPreprint
Liu, X.-G., Chen, X., Chen, B., & Fu, M. (2023) · Research Square · doi:10.21203/rs.3.rs-3240139/v1
Beronja, B., Filipović, T., Hrkalović, M., Maksimović, N., & Perović, D. (2023) · Glasnik javnog zdravlja · doi:10.5937/serbjph2302164b
Hohl, F. (2023) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-10039
Pakhan, A. A., Boob, M. A., Somaiya, K. J., et al. (2023) · Cureus · doi:10.7759/cureus.44032
“All people with osteoporosis benefit from exercise [14].”
BackgroundRen, T., Wu, P., Yin, S., You, H., Liu, T., Li, Z., Liu, Q., & Mao, J. J. J. (2023) · Research Square · doi:10.21203/rs.3.rs-3278794/v1
Phantom study of layered sensor module for photon-counting BMD detector
Byun, J., Kim, Y., Seo, J., et al. (2023) · Physical and Engineering Sciences in Medicine · doi:10.1007/s13246-023-01319-3
Osteoporose na pós-menopausa e a utilização de bisfosfonatos como opção terapêutica
Caires, L. T. V., Anjos, E. R. T. B. D., Silva, F. M. A. D., et al. (2023) · Brazilian Journal of Health Review · doi:10.34119/bjhrv6n4-279
The application of FRAX in Ecuador
Gavilánez, E. L., Johansson, H., Harvey, N. C., et al. (2023) · Revista Colombiana de Reumatología (English Edition) · doi:10.1016/j.rcreue.2021.07.006
Chongruangsri, N.-N., Jansisyanont, P., & Chuenchompoonut, V. (2019) · Chula Digiverse · doi:10.58837/chula.the.2019.381
Bone Considerations in Hip and Knee Arthroplasty
Nakasone, C. K., & Lim, S. Y. (2023) · Tissue repair and reconstruction · doi:10.1007/978-981-99-5826-9_7
Feng, Z., Jiang, Z., Cao, L., Li, T., He, Q., Hu, W., Chu, J., Chen, X., Liu, S., Han, Q., et al. (2023) · Journal of Public Health · doi:10.1007/s10389-023-02100-2
Perbandingan Kadar Kalsium pada Wanita Premenopause dan Menopause sebagai Faktor Risiko Osteoporosis
Abbas, M., Mus, R., Fitriana, F., et al. (2023) · MAHESA Malahayati Health Student Journal · doi:10.33024/mahesa.v3i10.11297
Gilani, M. A., Motten, T. L., & Khan, S. S. (2023) · Healthline · doi:10.51957/healthline_454_2022
“Osteoporosis affects more women after the menopause due to estrogen deficiency then pre-[2] menopausal women.”
BackgroundTERAPIA DE REPOSIÇÃO HORMONAL NA MENOPAUSA: ABORDAGENS ATUAIS E CONSIDERAÇÕES DE SEGURANÇA
Lima, L. B., Santos, J. S., Júnior, P. R. H., Hernandes, N. N. F., & Ferreira, C. V. (2023) · doi:10.22533/at.ed.6242318109
A INFLUÊNCIA DO USO DE COSMÉTICOS NO BEM-ESTAR DURANTE A PANDEMIA
Vaz, J. M. D. L., & Lubi, N. C. (2023) · doi:10.22533/at.ed.62423181018 · Cited by 1
AVANÇOS NEUROCIRÚRGICOS NO TRATAMENTO DA DOENÇA DE PARKINSON: UMA REVISÃO DA LITERATURA
Silva, A. M. D. S., Francisquine, M. E. D., Gomes, T. V., Júnior, P. R. H., Hernandes, N. N. F., Ferreira, R. D., Ambrosio, R. D., & Júnior, H. S. D. F. (2023) · doi:10.22533/at.ed.62423181010
A pesquisa em saúde: desafios atuais e perspectivas futuras 4
Cavalcanti, S. A. U. (2023) · doi:10.22533/at.ed.624231810
de Queiroz, A. B. L. M., Avelino, Á. I. D. S., Almeida, B. K. C., Filho, É. M. D. C., Costa, K. R., Campelo, L. M., Alencar, L. A., Lima, R. M., & da Silva, F. R. (2023) · doi:10.22533/at.ed.6242318103
ANÁLISE DOS MARCADORES DE ESTRESSE OXIDATIVO EM CORREDORES
Carvalho, N. D., de Oliveira, L. F. N., Nóbrega, E. C. M., da Silva, A. K. F., & Loureiro, A. C. C. (2023) · doi:10.22533/at.ed.62423181021
Pimentel, L. G. D., Carvalheira, G. M., Cezar, G. F. D. G., de Abreu, F. P. R., Barbosa, V. M., Júnior, P. R. H., Rosa, J. D. S., Hernandes, N. N. F., Bastos, R. M., & Côrtes, P. P. D. R. (2023) · doi:10.22533/at.ed.62423181019
EDUCAÇÃO EM SAÚDE E GRUPOS DE CONVIVÊNCIA DE PESSOAS IDOSAS: DIÁLOGOS POSSÍVEIS
dos Santos, R. G., Fioreze, C., & Barelli, C. (2023) · doi:10.22533/at.ed.6242318107
AVANÇOS E DESAFIOS DA CIRURGIA ROBÓTICA EM UROLOGIA: UMA REVISÃO DA LITERATURA
de Paiva, Á. T., da Cunha, A. C. B. G., Silva, M. A. D. S., de Oliveira, G. Q., dos Santos, V. O., Júnior, P. R. H., Rosa, J. D. S., Hernandes, N. N. F., Bastos, R. M., & Ambrosio, R. D. (2023) · doi:10.22533/at.ed.62423181017 · Cited by 1
Fernandes, F., de Oliveira, M. L., Casarin, F., VASQUES, B. S., Munhoz, O. L., & Ilha, S. (2023) · doi:10.22533/at.ed.62423181013
Ferreira, M. A. R., Mangiarini, C. B., Ibraim, M. F., Silva, G. A. L., Júnior, P. R. H., Rosa, J. D. S., Hernandes, N. N. F., Bastos, R. M., & Côrtes, P. P. D. R. (2023) · doi:10.22533/at.ed.6242318106
REDEFININDO O FUTURO: INOVAÇÕES EM PRÓTESES ORTOPÉDICAS PARA OSTEONECROSE DA CABEÇA DO FÊMUR
Henriques, L. C. M., Júnior, P. R. H., Hernandes, N. N. F., & Júnior, H. S. D. F. (2023) · doi:10.22533/at.ed.62423181015
ATENÇÃO À QUEDA DE IDOSOS NA SAÚDE PÚBLICA
Pereira, E. M., de Morais, J. A., Batista, D. N., de Oliveira, M. V. D., dos Santos, E. N., Alcântara, A. L. G., Santana, E. C., de Oliveira, J. R. G., da Silva, C. M. O., Leite, J. C. P., et al. (2023) · doi:10.22533/at.ed.6242318101
SARCOPENIA NA ERA MODERNA: DESVENDANDO NOVOS HORIZONTES NO MANEJO DO IDOSO SARCOPÊNICO
dos Santos, C. C., Júnior, P. R. H., Hernandes, N. N. F., & Júnior, H. S. D. F. (2023) · doi:10.22533/at.ed.62423181012
Shan, S., Chen, Y., & Zhang, Z. (2023) · Research Square · doi:10.21203/rs.3.rs-3452254/v1
Nguyen, T., & Yu, A. (2023) · Cureus · doi:10.7759/cureus.47998
“Most guidelines addressing decreased BMD underscore fragility fractures as the definitive criterion for initiating pharmacologic therapy [11,14].”
BackgroundA bibliometric analysis of the top 50 most cited articles on osteoporotic fractures
Yadav, R., Raja, B., Sudhakar, P. V., Mongia, A., & Kurmi, A. (2022) · Journal of the Uttaranchal Orthopaedic Association · doi:10.4103/juoa.juoa_6_22
Diagnosis dan penatalaksanaan osteosarkopenia pada penderita sistemik lupus eritematosus
Tejawati, D. A. K., Gunadi, I. W. H., Kambayana, G., Putrawan, I. B. P., & Kurniari, P. K. (2023) · Intisari Sains Medis · doi:10.15562/ism.v14i2.1717 · Cited by 1
Sriploy, P. (2016) · Chula Digiverse · doi:10.58837/chula.the.2016.1723 · Cited by 1
Miller, C. J. (2023) · Queensland University of Technology · doi:10.5204/thesis.eprints.244742
de Oliveira, C. H. N., Pereira, C. D. O., Loureiro, L. F., et al. (2023) · Brazilian Journal of Health Review · doi:10.34119/bjhrv6n6-246
Trầm, T. T., & Huỳnh, T. H. (2023) · Tạp chí Y Dược học Cần Thơ · doi:10.58490/ctump.2023i66.1247
ARTICULAR SYNDROME IN THE ELDERLY: COMMON DIFFERENTIALS AND CHALLENGES
Mruthyunjaya, P., & Nadella, M. (2023) · Anti-Aging Eastern Europe · doi:10.56543/aaeeu.2023.2.3.07
Montini, M., Pagani, A. A. M., Sporeni, S., & Longhi, E. V. (2023) · Springer eBooks · doi:10.1007/978-3-031-31307-3_30
Hernández, G. D. J. L. (2023) · UVaDOC UVaDOC University of Valladolid Documentary Repository (University of Valladolid) · doi:10.35376/10324/63685
Evaluation of Osteosarcopenia and Biochemical Parameters in People Living with HIV
Tuna, M., & Çakırca, T. D. (2023) · Flora the Journal of Infectious Diseases and Clinical Microbiology · doi:10.5578/flora.20239608
Clinical risk factors analysis and prevention of osteoporosis as a complication of diabetes
Wang, J., Li, H., Zhu, H., Xie, X., Zheng, Q., Qu, J., Yuan, H., Liu, T., & Lu, Q. (2023) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-023-01303-3
“OP is a common chronic bone disease that is mainly characterized by reduced bone density, increased porosity, and increased susceptibility to fracture [13, 14].”
Osteoporosis and Periodontitis: The Bi-Directional Link
Dhande, S. R. (2022) · Clinical Orthopaedics and Trauma Care · doi:10.31579/2694-0248/028
Impact of COVID-19 Pandemic on Osteoporosis Screening using Dual-Energy X-ray Absorptiometry
Hisatomi, L. A. (2022) · Orthopedics and Rheumatology Open Access Journal · doi:10.19080/oroaj.2022.20.556048
Does Being Treated for Osteoporosis Mean "Awareness"?
Ünal, Z. K., Akalın, A. E. Ş., Sezer, M. K., et al. (2024) · European Journal of Therapeutics · doi:10.58600/eurjther1948
Ignasimuthu, A., & Parimala, S. (2022) · Journal of Dr. YSR University of Health Sciences. · doi:10.4103/jdrntruhs.jdrntruhs_185_22
Klinik Uygulama Rehberleri Ebelik & Kadın Sağlığı
Akça, E. İ., Köroğlu, C. O., Demir, E., Alan, S., Öztürk, M., Akbaş, M., Dağlar, G., Güler, H., Özcan, H., Tokat, M. A., et al. (2022) · Akademisyen Kitabevi eBooks · doi:10.37609/akya.1139
Jang, M. U., Kim, M. S., Kwon, Y.-M., Hwang, J., Subramanian, S. A., Kim, S., Kim, S. J., Cho, S. W., & Sung, I. (2024) · Research Square · doi:10.21203/rs.3.rs-3950583/v1
Determination of Risk Factors of Osteoporosis in the Community of Post-Menopausal Age
Perveen, R., Shabbir, A., Azad, Z., & Azad, A. (2023) · Pakistan Journal of Health Sciences · doi:10.54393/pjhs.v5i02.1230
Celiac disease in adult patients
Ciacci, C., Micco, I. D., Stefano, M. D., & Mengoli, C. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13359-6.00001-7
Bone Quality in Spinal Surgery: Evaluation, Implications, and Treatments
Raad, M., Satin, A. M., & Derman, P. B. (2024) · Contemporary Spine Surgery · doi:10.1097/01.css.0001009828.37677.64
Soroush, M. G. Z., Kazemi, A., & Ahkiani, M. (2024) · Annals of Military and Health Sciences Research · doi:10.5812/amh-143361
Hamoda, N. Z., El-Tokhy, H. M., Mohamed, E. F., & Mohammed, D. S. (2020) · The Scientific Journal of Al-Azhar Medical Faculty Girls · doi:10.4103/sjamf.sjamf_52_20
Tungjai, M., Tapanya, M., Htun, K. T., Padngam, S., Thumvijit, T., Sriburee, S., Chinchai, P., Pornwiang, S., & Kothan, S. (2024) · Journal of Associated Medical Sciences · doi:10.12982/jams.2024.034
Jerban, S., Moazamian, D., Ma, Y., Afsahi, A. M., Dwek, S., Athertya, J., Malhi, B. S., Jang, H., Woods, G. N., Chung, C. B., et al. (2024) · Quantitative Imaging in Medicine and Surgery · doi:10.21037/qims-23-1341
“Bone loss in osteoporosis (OPo) which define as Dual-Energy X-ray Absorptiometry (DXA) T-scores below −2.5 and in its earlier stage disease, osteopenia (OPe) which define as DXA T-scores between −2.5 and −1 in the clinical approaches, may be linked with the tendon quality decline (7,10-12).”
BackgroundInfluential
Metadata
- Authors
- Cosman, F., de Beur, S. J., LeBoff, M. S., Lewiecki, E. M., Tanner, B., Randall, S., & Lindsay, R.
- Affiliations
- Helen Hayes Hospital (US)
- Brigham and Women's Hospital (US)
- New Mexico Clinical Research & Osteoporosis Center (US)
- Bone Health and Osteoporosis Foundation (US)
- Corresponding author
- Cosman, F.
- Venue
- Osteoporosis International
- Published
- 2014-08-15
- Volume
- 25
- Issue
- 10
- Pages
- 2359-2381
- ISSN
- 0937-941X (ISSN-L)
- 1433-2965
- PMC
- PMC4176573
- OpenAlex
- W2171709369
- Semantic Scholar
- 91c0d02cdbd4c5dd69ed206e6a0b2b94c9aa0830
- Cited by
- 4,149
- References
- 101
- Citations by year
- 2026: 141 · 2025: 226 · 2024: 267 · 2023: 292 · 2022: 351 · 2021: 415 · 2020: 458 · 2019: 336 · 2018: 311 · 2017: 304 · 2016: 285 · 2015: 246 · 2014: 141
- FWCI
- 242.08
- Type
- journal article
- Language
- en
- Update notices
- correction (2015-05-19)
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Osteoporosis International (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- PubMed Central (submittedVersion, cc-by-nc)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Surgery › Hip and Femur Fractures
- Keywords
- osteoporosis, osteoporosis prevention, osteoporosis treatment, bone health, osteoporosis drugs
- MeSH terms
- Aged, Calcium, Dietary, Diet, Female, Humans, Male, Middle Aged, Osteoporosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.